Urgent

Cytomegalovirus (CMV) end-organ disease

CMV · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

CMV causes end-organ disease (retinitis, colitis, pneumonitis, encephalitis) mainly in advanced HIV, transplant recipients and other immunosuppressed hosts. Prompt antiviral therapy prevents irreversible damage, particularly vision loss in retinitis.

Red flags

  • Any visual blurring/floaters in immunosuppressed (retinitis)
  • Haematochezia or perforation signs (colitis)
  • Hypoxia with diffuse infiltrates (pneumonitis)
  • Altered consciousness (encephalitis/ventriculitis)
  • Rising viral load despite therapy (resistance)

Assessment

Differential diagnosis

  • Other opportunistic infection (toxoplasma, PCP, cryptococcus)
  • Immune reconstitution uveitis
  • HIV-related or drug-induced colitis
  • Rejection in transplant recipients
  • Other viral end-organ disease (HSV, adenovirus)

Investigations

  • CMV PCR (blood viral load) and tissue PCR where applicable
  • Dilated fundoscopy by ophthalmology for retinitis
  • Endoscopy with biopsy for colitis (CMV inclusions/immunostain)
  • CD4 count and HIV viral load
  • Bronchoalveolar lavage for pneumonitis
  • CSF CMV PCR for neurological disease

Management

  • Identify host immunosuppression and localise end-organ involvement
  • Confirm with CMV PCR and tissue histology/immunostaining where feasible
  • Arrange urgent ophthalmology review if any visual symptoms
  • Start systemic antiviral therapy promptly (induction then maintenance)
  • For sight-threatening retinitis consider intravitreal therapy plus systemic
  • Reduce immunosuppression where safe in transplant recipients
  • In HIV, start or optimise ART (watch for immune recovery uveitis)
  • Monitor CMV viral load response and renal/marrow toxicity of antivirals
  • Continue maintenance until immune recovery (e.g. CD4 over 100 for 3-6 months)
  • Screen for and manage antiviral resistance if poor response
  • Provide supportive care and manage complications
  • Arrange ophthalmology follow-up for retinal detachment risk

Drugs & doses

Ganciclovir 5 mg/kg IV every 12 h induction for 14-21 days
Valganciclovir 900 mg PO twice daily induction then 900 mg once daily maintenance
Foscarnet 60 mg/kg IV every 8 h (ganciclovir resistance/intolerance)
Ganciclovir intravitreal injection for sight-threatening retinitis (adjunct)

Disposition

Admit for induction if severe; urgent ophthalmology; specialist ID/transplant co-management.

Complications & pitfalls

  • Irreversible blindness and retinal detachment
  • Gastrointestinal haemorrhage/perforation
  • Immune recovery uveitis after ART
  • Marrow suppression (ganciclovir) and nephrotoxicity (foscarnet)
  • Antiviral resistance

Exam pearls

  • Zone 1 retinitis threatening the macula/optic nerve needs intravitreal plus systemic therapy
  • Valganciclovir oral bioavailability allows outpatient induction in stable retinitis
  • Monitor neutrophils on ganciclovir; add G-CSF if needed
  • In HIV, restoring immunity is the definitive treatment
  • Resistance testing (UL97/UL54) guides switch to foscarnet/cidofovir

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.